Saturday - July 5, 2025
Datroway Approved in the US for Patients With Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
June 25, 2025
WILMINGTON, Delaware, June 25 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

Based on TROPION-Lung05 results and supported by data from TROPION-Lung01

First and only TROP2-directed therapy approved in the US for the treatment of lung cancer

*

DATROWAY (datopotamab deru . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products